Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity? 
Via Benzinga
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility. 
Via The Motley Fool
Are Diet Drug Companies Over The Hump?
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation. 
Via Talk Markets
Topics Stocks / Equities
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021. 
Via Benzinga
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Eli Lilly Unusual Options Activity
Via Benzinga
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top Research Reports For Eli Lilly, PepsiCo & Morgan Stanley
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., PepsiCo, Inc., and Morgan Stanley. 
Via Talk Markets
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The future remains uncertain. 
Via Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with favorable safety data. 
Via Benzinga
Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
Jim Cramer recommends buying hated stock Eli Lilly, while also praising Coinbase and IES Holdings. Marvell and Apple are also solid bets. 
Via Benzinga
The Smartest Megacap Growth ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's Phase 3 SUMMIT trial results show tirzepatide's potential to reduce heart failure risk and improve symptoms in obese adults with HFpEF. 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Via The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic. 
Via Benzinga
Topics Economy
Exposures Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
These stocks have realistic paths to grow larger than Tesla. 
Via The Motley Fool
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
An analysis and commentary on the financial markets. 
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years. 
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
These are income stocks you can buy and hold forever. 
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.